Catabasis Names Ex-Alkermes Exec Komjathy Chief Commercial Officer
Andrew Komjathy has been appointed chief commercial officer of Catabasis Pharmaceuticals (NASDAQ: CATB). He joins the Cambridge, MA, drug developer from Alkermes (NASDAQ: ALKS), where he was vice president of commercial sales. His experience also includes positions at Genzyme, Shire, and Biogen (NASDAQ: BIIB). Catabasis has changed its therapeutic focus several times
, having pursued drugs for diabetes and high cholesterol among other diseases. Its most advanced compound, edasalonexent, is in Phase 3 testing in Duchenne muscular dystrophy.
More from EXOME
Trending on Xconomy
Underwriters and Partners
Xconomy Insight · Special Report
How to Jump 5 Unforeseen Hurdles to Biotech Success – Startup Sourcebook
Insights, wisdom, and inspiration on what it takes
Sponsored · Whitepaper
Monitoring Solutions for Pharma-CRO/CMO Partnerships to Maintain Quality & Timelines
Implementing electronic solutions for risk mitigation
XiltriX
Sponsored · Whitepaper
Protecting Valuable Life Science Assets & Equipment: Monitoring Solutions
Remain compliant and ensure optimal productivity
XiltriX
Investment in Wisconsin startups reaches new record total
Tax credits help tech innovators attract capital, fuel growth
Wisconsin Economic Development Corporation